公开(公告)号：EP3067356B1

公开(公告)日：2018-07-04

申请号：EP14859491.4

申请日：2014-11-06

申请人： ONO Pharmaceutical Co., Ltd.

发明人： INUKAI, Takayuki ,  TAKEUCHI, Jun ,  YASUHIRO, Tomoko ,  WOLF, Mark Allan ,  PAWAR, Vijay Dattaram ,  CHAKRABARTI, Anjan ,  CHITTIMALLA, Santhosh Kumar

IPC分类号： C07D487/04 ,  A61K31/519 ,  A61P9/00 ,  A61P13/12 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  A61P37/02 ,  A61P43/00

CPC分类号： C07D487/04

摘要： The compound represented by general formula (I) has strong Axl inhibition activity by means of a pyridone ring structure being introduced into a pyrrolo pyrimidine skeleton, and so the result can serve as a treatment agent for Axl-related diseases, for example cancers such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glial tumors, renal disease, immune system disorders, and cardiovascular disease.

公开(公告)号：EP3067356A1

公开(公告)日：2016-09-14

申请号：EP14859491.4

申请日：2014-11-06

申请人： ONO Pharmaceutical Co., Ltd.

发明人： INUKAI, Takayuki ,  TAKEUCHI, Jun ,  YASUHIRO, Tomoko ,  WOLF, Mark Allan ,  PAWAR, Vijay Dattaram ,  CHAKRABARTI, Anjan ,  CHITTIMALLA, Santhosh Kumar

IPC分类号： C07D487/04 ,  A61K31/519 ,  A61P9/00 ,  A61P13/12 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  A61P37/02 ,  A61P43/00

CPC分类号： C07D487/04

摘要： The compound represented by general formula (I) has strong Axl inhibition activity by means of a pyridone ring structure being introduced into a pyrrolo pyrimidine skeleton, and so the result can serve as a treatment agent for Axl-related diseases, for example cancers such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glial tumors, renal disease, immune system disorders, and cardiovascular disease.

摘要翻译： 通式（I）表示的化合物通过将吡啶酮环结构引入吡咯并嘧啶骨架中而具有强Axl抑制活性，因此其结果可用作Axl相关疾病的治疗剂，例如癌症例如 急性骨髓性白血病，黑色素瘤，乳腺癌，胰腺癌和神经胶质瘤，肾病，免疫系统疾病和心血管疾病。

公开(公告)号：EP3228615A1

公开(公告)日：2017-10-11

申请号：EP15865945.8

申请日：2015-12-03

申请人： ONO Pharmaceutical Co., Ltd.

发明人： KUSUMI, Kensuke ,  KURATA, Haruto ,  NAGANAWA, Atsushi ,  KODERA, Yasuyo ,  INAGAKI, Yuichi ,  TAKIZAWA, Hiroya ,  WOLF, Mark Allan ,  RAKER, Joseph

IPC分类号： C07D205/04 ,  C07D207/16 ,  C07D401/10 ,  C07D403/10 ,  A61K31/397 ,  A61K31/40 ,  A61P25/28 ,  A61P31/00 ,  A61P35/00 ,  A61P37/02 ,  A61P43/00 ,  A61K31/4427 ,  A61K31/404

CPC分类号： C07C13/48 ,  A61K31/015 ,  A61K31/19 ,  A61K31/397 ,  C07C13/20 ,  C07C2602/10 ,  C07D205/04 ,  C07D207/16 ,  C07D401/10 ,  C07D403/10

摘要： A compound shown by general formula (I)
(in the formula, all of the symbols are as defined in the specification) has selective S1P5 receptor agonist activity due to having a linker from a phenyl group to a cyclic substituent in a dihydronaphthalene skeleton; i.e., due to having a short linker of one atom or less as L in general formula (I), and can therefore serve as an agent for the treatment of S1P5-mediated diseases, e.g., neurodegenerative diseases such as schizophrenia.

摘要翻译： 由通式（I）表示的化合物（式中所有符号如说明书中所定义）由于在二氢萘骨架中具有从苯基到环状取代基的连接基而具有选择性S1P5受体激动剂活性; 即由于在通式（I）中具有1个原子或更少的L的短接头，因此可用作治疗S1P5介导的疾病例如神经变性疾病如精神分裂症的药剂。